{"nctId":"NCT01449682","briefTitle":"Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.","startDateStruct":{"date":"2011-10"},"conditions":["Retinal Vein Occlusion","Macular Edema"],"count":10,"armGroups":[{"label":"Ozurdex PRN","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ozurdex"]},{"label":"Ozurdex Q16 weeks","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ozurdex"]}],"interventions":[{"name":"Ozurdex","otherNames":["Dexamethasone implant, DEX implant"]},{"name":"Ozurdex","otherNames":["dexamethasone implant, DEX implant"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Presence of central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO)\n* Prior treatment with \\>= 2 intravitreal anti-VEGF injections but no treatment in last 45 days.\n* Age 18 years or older\n* ETDRS Visual acuity between 3 and 72 letters and approximate Snellen equivalent of 20/25 to 20/800\n* Central foveal thickness \\>275 microns or presence of cystic edema on OCT studies.\n* For sexually active women of childbearing potential, agreement to the use of an appropriate form of contraception (or abstinence) for the duration of the study.\n* Ability to provide written informed consent â€¢ Capable of complying with study protocol\n\nExclusion Criteria:\n\n* History of steroid-related glaucoma (steroid response) requiring more than one topical glaucoma medication.\n* Intraocular injection of steroid medication within prior 4 months\n* Evidence of significant retinal ischemia on fluorescein angiography in the opinion of the treating physician.\n* Previous laser photocoagulation within 4 months of study\n* Concurrent ocular disease (e.g proliferative diabetic retinopathy, geographic atrophy) that would limit visual acuity in the opinion of the treating physician\n* Patients who are pregnant.\n* Unwilling or unable to follow or comply with all study related procedures.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Macular Function Using Microperimetry","description":"To determine if there is change in mean macular sensitivity using microperimetry at 48 weeks compared to baseline for both the PRN and Q16weeks treatment groups","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"0.8"},{"groupId":"OG001","value":"12.7","spread":"2.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"1.7"},{"groupId":"OG001","value":"10.7","spread":"1.9"}]}]}]},{"type":"PRIMARY","title":"Macular Function Using Multi-focal ERG","description":"To determine if there is a change in central amplitude responses using multifocal ERG at 48 weeks compared to baseline values for both the PRN and Q16weeks treatment groups","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","spread":"0.39"},{"groupId":"OG001","value":"6.62","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.20","spread":"4.03"},{"groupId":"OG001","value":"30.18","spread":"9.60"}]}]}]},{"type":"SECONDARY","title":"To Determine if There is a Change in Visual Acuity (Number of ETDRS Letters) at 48 Weeks Compared to Baseline Values for Both the PRN and Q16weeks Treatment Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4","spread":"7.1"},{"groupId":"OG001","value":"55.6","spread":"7.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":"8.4"},{"groupId":"OG001","value":"53.2","spread":"8.5"}]}]}]},{"type":"SECONDARY","title":"To Determine if There is a Change in Central Foveal Thickness (Microns on High Resolution OCT) at 48 Weeks Compared to Baseline Values for Both the PRN and Q16weeks Treatment Groups","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"501.7","spread":"59.7"},{"groupId":"OG001","value":"353.5","spread":"27.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"361.4","spread":"47.3"},{"groupId":"OG001","value":"326.7","spread":"21.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":5},"commonTop":["Elevated Intraocular Pressure"]}}}